In parallel, since the use of PARPi in advanced BC patients bearing germline inactivating alterations in BRCA1 or BRCA2 genes has resulted in improved patient PFS [66,152] and, in the case of olaparib in patients not previously treated with chemotherapy, in improved OS [170], the assessment of germline BRCA1/2 status (where indicated) should parallel the intratumor evaluation of PD-L1 by IHC for the choice of the best therapy for patients with advanced mTNBC. The gene discussed is BRCA2; the disease is breast cancer.